The goal of this work was to appraise the after-effects of radiotherapy and associated radio- and chemotherapy on hematosarcomas by studying the granulocytic progenitor cells (CFUc). The bone marrow of 14 subjects was cultured in methylcellulose 1--6.5 years after completion of radiotherapy. The results were recorded as the number of CFUc per 10(5) nucleated medullary cells plated and per 10(5) metamyelocytes plated, and the total number of medullary CFUc was calculated. These different modes of expression are discussed. The post-radiotherapeutic effects appeared to be closely correlated with the volum irradiated. Chemotherapy seemed in several cases to accentuate the effects. Nevertheless, the organism can operate a powerful compensatory mechanism by means of increased mitosis, and in addition, certain subjects are able to maintain a normal number of CFUc after an aggressive treatment. It was possible in certain cases to study the medullary regeneration of the irradiated zone by culture of the CFUc and by the 59Fe external counting. Its extent after radiotherapy seemed for both the granulocytic and the red cell line to be correlated with the volume irradiated. Subject to the study of new cases, regeneration appears to be very reduced when chemotherapy is associated with radiotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-3-642-81249-1_22 | DOI Listing |
Turk J Haematol
January 2025
Tianjin Medical University General Hospital, Department of Hematology, Tianjin, P. R. China.
Objective: Immune-related pancytopenia (IRP) is characterized by autoantibody-mediated destruction or suppression of bone marrow cells, leading to pancytopenia. This study aimed to explore the role of TRAPPC4 (trafficking protein particle complex subunit 4) as a key autoantigen in IRP, including epitope identification and immune activation mechanisms.
Methods: A total of 90 participants were included in the study, divided into four groups: 30 newly diagnosed IRP patients, 25 IRP remission patients, 20 patients with control hematologic conditions (severe aplastic anemia [SAA] and myelodysplastic syndrome [MDS]), and 15 healthy controls.
Stem Cells Dev
January 2025
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Autologous hematopoietic stem cell transplantation is used to restore bone marrow function after high-dose chemotherapy. For apheresis, granulocyte colony-stimulating factor (G-CSF) is standard of care, but obtaining sufficient stem cells can be challenging. Other mobilization agents include plerixafor and PEGylated G-CSF (PEG-G-CSF).
View Article and Find Full Text PDFSci China Life Sci
January 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Hematopoiesis is a finely tuned process that generates all blood cell types through self-renewal and differentiation, which is crucial for maintaining homeostasis. Acute infections can prompt a hematopoietic response known as emergency myelopoiesis. In this study, using a Candida albicans (C.
View Article and Find Full Text PDFJ Clin Invest
January 2025
Department of Laboratory Medicine, Division of Translational Cancer Researc, Lund University Cancer Centre, Lund University, Lund, Sweden.
The biology centered around the TGF-beta type I receptor Activin Receptor-Like Kinase (ALK)1 (encoded by ACVRL1) has been almost exclusively based on its reported endothelial expression pattern since its first functional characterization more than two decades ago. Here, in efforts to better define the therapeutic context in which to use ALK1 inhibitors, we uncover a population of tumor-associated macrophages (TAMs) that, by virtue of their unanticipated Acvrl1 expression, are effector targets for adjuvant anti-angiogenic immunotherapy in mouse models of metastatic breast cancer. The combinatorial benefit depended on ALK1-mediated modulation of the differentiation potential of bone marrow-derived granulocyte-macrophage progenitors, the release of CD14+ monocytes into circulation, and their eventual extravasation.
View Article and Find Full Text PDFClin Transl Sci
January 2025
Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Granulocyte colony-stimulating factor (G-CSF) mobilizes peripheral blood (PB) progenitor cells from bone marrow (BM) into circulation for PB stem cell transplantation (PBSCT). This study aimed to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model of filgrastim in healthy subjects to optimize PB CD34 cell collection. Plasma filgrastim concentrations and CD34 cell count data were obtained from a clinical study involving healthy Korean subjects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!